Donepezil

E133125

Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (5)

Label Occurrences
Aricept 3
Donepezil canonical 2
Aricept ODT 1

Statements (62)

Predicate Object
instanceOf acetylcholinesterase inhibitor
cholinesterase inhibitor
medication
piperidine derivative
approvedBy Food and Drug Administration
surface form: U.S. Food and Drug Administration
ATCCode N06DA02
canBeUsedWith memantine
cautionIn patients with COPD
patients with asthma
patients with bradycardia
patients with cardiac conduction abnormalities
patients with peptic ulcer disease
chemicalFormula C24H29NO3
coMarketedBy Pfizer
commonSideEffect anorexia
diarrhea
fatigue
insomnia
muscle cramps
nausea
vomiting
contraindication hypersensitivity to donepezil
crosses blood–brain barrier
developedBy Eisai
doesNotCure Alzheimer's disease
dosageForm oral tablet
orally disintegrating tablet
effect slows cognitive decline in Alzheimer's disease
eliminationHalfLife about 70 hours
FDAApprovalYear 1996
hasBrandName Donepezil self-linksurface differs
surface form: Aricept

Donepezil self-linksurface differs
surface form: Aricept ODT
hasGenericName donepezil
hasHigherDoseStrength 23 mg once daily
hasINN Donepezil self-linksurface differs
surface form: donepezil
hasMolecularWeight 379.50 g/mol
hasUSAN donepezil
increasesLevelOf acetylcholine in the brain
isListedOn World Health Organization Model List of Essential Medicines
isSelectiveFor central nervous system acetylcholinesterase
legalStatusEU prescription only
legalStatusUS prescription only
mechanismOfAction reversible inhibition of acetylcholinesterase
metabolizedBy CYP2D6
CYP3A4
pregnancyCategoryUS C
proteinBinding high
routeOfAdministration oral
seriousSideEffect bradycardia
gastrointestinal bleeding
seizures
syncope
taken once daily
usually at bedtime
treats Alzheimer's disease
mild Alzheimer's disease
moderate Alzheimer's disease
severe Alzheimer's disease
typicalMaintenanceDose 5–10 mg once daily
typicalStartingDose 5 mg once daily
usedFor cognitive symptoms of Alzheimer's disease
dementia associated with Alzheimer's disease

How these facts were elicited

The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.

Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10.

# Requirements
- If you don't know the subject at all, return an empty list.
- If the subject is not a named entity, return an empty list.
- Include at least one triple where predicate is "instanceOf".
- Do not get too wordy.
- Separate several objects into multiple triples with one object.
Input
Subject: Donepezil
Description of subject: Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.

Referenced by (8)

Full triples — surface form annotated when it differs from this entity's canonical label.

Eisai hasProduct Donepezil
Eisai hasProduct Donepezil
this entity surface form: Aricept
Eisai developed Donepezil
Eisai developed Donepezil
this entity surface form: Aricept
Eisai developedForIndication Donepezil
this entity surface form: Donepezil – Alzheimer’s disease
Donepezil hasINN Donepezil self-linksurface differs
this entity surface form: donepezil
Donepezil hasBrandName Donepezil self-linksurface differs
this entity surface form: Aricept
Donepezil hasBrandName Donepezil self-linksurface differs
this entity surface form: Aricept ODT